← Leaderboards
Archie N Tse
Sloan-Kettering Inst Can Research
$641,256
Attributed
$641,256
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $239.6K · FY2006–09$250K$187.5K$125K$62.5K$0
'06
'07
'08
'09
Funding mix
By agency
NIH$641,256 · 1
By mechanism
K08$641,256 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Olga A Guryanova$2,670,428
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsCytotoxic AgentAdvanced Malignant NeoplasmAmerican Society Of Clinical OncologyCorrelative Study7-HydroxystaurosporineAmerican Association Of Cancer ResearchBaseBasic ScienceBiochemicalAnalogCombined Modality TherapyBiopsyCancer TherapyAwardCell Cycle CheckpointCell DeathCellsCheckpoint Kinase 1Chemotherapeutic AgentChemotherapyClientClinical ResearchCytotoxic Chemotherapy
Grant awards (5)
Targeting Cell Cycle Checkpoints in Cancer Therapeutics$133,893
K08 · FY2009 · CA · contact PI
Targeting Cell Cycle Checkpoints in Cancer Therapeutics$105,684
K08 · FY2009 · CA · contact PI
Targeting Cell Cycle Checkpoints in Cancer Therapeutics$133,893
K08 · FY2008 · CA · contact PI
Targeting Cell Cycle Checkpoints in Cancer Therapeutics$133,893
K08 · FY2007 · CA · contact PI
Targeting Cell Cycle Checkpoints in Cancer Therapeutics$133,893
K08 · FY2006 · CA · contact PI